Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...
Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...
Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet ...
Novo Nordisk (NVO) and Valo Health expand collaboration to develop new treatments targeting cardiometabolic diseases. Read ...
Novo Nordisk warns that adding liraglutide to the 503B Bulks List would contradict Congress’ and the FDA’s intent to restrict patient exposure to unapproved drugs. The company argues that such ...
The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...
If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...
Novo's drug candidate, CagriSema, showed weight loss below expectations during a trial, dealing a blow to the company's plans ...
Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and ...
In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...
GlobalData on MSN1d
Novo Nordisk and Valo expand cardiometabolic drug partnershipNovo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback